Insulin Resistance Syndrome: Difference between revisions
imported>Nancy Sculerati MD No edit summary |
imported>Petréa Mitchell m (Big Cleanup) |
||
Line 3: | Line 3: | ||
[[Category:CZ Live]] | [[Category:CZ Live]] | ||
[[Category:Health Sciences]] | [[Category:Health Sciences Workgroup]] |
Revision as of 09:30, 6 April 2007
The insulin resistance syndrome is a "constellation of findings, including central obesity, glucose intolerance, dyslipidemia, and hypertension, that promotes the development of type 2 diabetes mellitus, cardiovascular disease, cancer, polycystic ovarian disease (PCOS), and nonalcoholic fatty liver disease".(reference for quote: Sudha B. Biddinger & C. Ronald Kahn : FROM MICE TO MEN: Insights into the Insulin Resistance Syndromes.Annual Review of Physiology Vol. 68: 123-158 (Volume publication date January 2006) (doi:10.1146/annurev.physiol.68.040104.124723)). As obesity has reached epidemic proportions in many countries of the developed world, a pattern of these findings has become recognized. Also called the metabolic syndrome, the dysmetabolic syndrome, or syndrome, this association of physiologic findings is the focus of current research in medicine.